BR112022006678A2 - Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas - Google Patents

Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Info

Publication number
BR112022006678A2
BR112022006678A2 BR112022006678A BR112022006678A BR112022006678A2 BR 112022006678 A2 BR112022006678 A2 BR 112022006678A2 BR 112022006678 A BR112022006678 A BR 112022006678A BR 112022006678 A BR112022006678 A BR 112022006678A BR 112022006678 A2 BR112022006678 A2 BR 112022006678A2
Authority
BR
Brazil
Prior art keywords
active substances
physiologically active
highly
lipophhilic
controlled release
Prior art date
Application number
BR112022006678A
Other languages
English (en)
Portuguese (pt)
Inventor
Nowak Mirko
Jesko Nowak Jay
Grave Annette
Wentzlaff Monika
Barthold Sarah
Geugelin Christian
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of BR112022006678A2 publication Critical patent/BR112022006678A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022006678A 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas BR112022006678A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203549.1A EP3808336A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079244 WO2021074399A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
BR112022006678A2 true BR112022006678A2 (pt) 2022-07-12

Family

ID=68281165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006678A BR112022006678A2 (pt) 2019-10-16 2020-10-16 Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas

Country Status (10)

Country Link
US (1) US20240148758A1 (https=)
EP (2) EP3808336A1 (https=)
JP (2) JP7850068B2 (https=)
CN (1) CN114929197A (https=)
AU (1) AU2020366134B2 (https=)
BR (1) BR112022006678A2 (https=)
CA (1) CA3157693A1 (https=)
IL (1) IL292019A (https=)
MX (1) MX2022004522A (https=)
WO (1) WO2021074399A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US20130338220A1 (en) * 2010-10-05 2013-12-19 Mark Tepper Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
AU2014340709B2 (en) 2013-10-29 2019-07-04 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
EP3808341A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Also Published As

Publication number Publication date
JP2022553652A (ja) 2022-12-26
CN114929197A (zh) 2022-08-19
JP2026034780A (ja) 2026-02-27
AU2020366134A1 (en) 2022-05-26
MX2022004522A (es) 2022-09-19
IL292019A (en) 2022-06-01
CA3157693A1 (en) 2021-04-22
US20240148758A1 (en) 2024-05-09
JP7850068B2 (ja) 2026-04-22
EP4045007A1 (de) 2022-08-24
EP3808336A1 (de) 2021-04-21
AU2020366134B2 (en) 2026-04-23
WO2021074399A1 (de) 2021-04-22

Similar Documents

Publication Publication Date Title
MX2020006965A (es) Formulacion farmaceutica oral que comprende cannabinoides y poloxamero.
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
EP3873442A4 (en) ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
BR112021006392A2 (pt) moduladores da alfa-1 antitripsina
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
CR20230149A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas (divisional exp no 2022-539)
BR112022007947A2 (pt) Uso de modulador de splicing para tratamento que retarda a progressão da doença de huntington
BR112017024517A2 (pt) compostos de tetraidroquinolinona como moduladores ror gama
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
PY2039449A (es) Inhibidortes tricíclicos de kars dependientes de akr1c3
BR112019014985A8 (pt) Composição estável de ingrediente ativo lipossolúvel, microcápsula e processo de preparação e uso da mesma
BR112018067322A2 (pt) composições de perfume
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
BR112022006643A2 (pt) Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas
BR112018070060A2 (pt) composições para tratamento bucal com uma exibição de sabor eficiente
CO2022008308A2 (es) Tieniloxazolonas y análogos
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
MX2021007084A (es) Una composicion antimicrobiana.
CR20220292A (es) Tiofenocarboxamidas sustituidas y sus derivados
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
BR112022008457A2 (pt) Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
BR112017016794A2 (pt) microcápsulas que conferem nota de odor intenso de baunilha
CL2021000930A1 (es) Piridazinas novedosas

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]